What is Respiri?
Respiri Limited, formerly iSonea Limited, is an Australian-based e-health company specializing in the research, development, and commercialization of medical devices and mobile health applications. The company's flagship product, Wheezo, is an innovative asthma management tool designed to empower users by providing comprehensive insights into their condition. Wheezo tracks triggers, symptoms, medication usage, and other relevant events, offering a data-driven approach to managing respiratory health. The company operates in both Australia and Israel, positioning itself as a key player in the digital health landscape.
How much funding has Respiri raised?
Respiri has raised a total of $12.5M across 1 funding round:
Stock Offering
$12.5M
Stock Issuance/Offering (2020): $12.5M, investors not publicly disclosed
What's next for Respiri?
The recent major strategic investment signals a pivotal moment for Respiri, likely indicating a transition into a scaling phase. This capital will be instrumental in expanding its market reach, further developing its technological capabilities, and potentially exploring new therapeutic areas within respiratory care. The focus on enterprise-level funding suggests strong confidence from investors in Respiri's business model and its potential for significant market impact. Future developments will likely center on enhancing the Wheezo platform and broadening its adoption among healthcare providers and patients.
See full Respiri company page
